New PKU drink passes small taste and tolerance test
NCT ID NCT04679467
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether people with phenylketonuria (PKU) can tolerate and stick with a new protein substitute called PKU Sphere. Thirteen participants gradually increased their intake over up to 16 weeks, then continued for 4 more weeks while researchers tracked their blood levels, gut symptoms, and how much they liked the product. The goal was to see if PKU Sphere is a practical option for managing PKU.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PKU Sphere (a protein substitute made from glycomacropeptide)
What this could lead to
If successful, this could provide a more acceptable and easier-to-use protein substitute for people with PKU, helping them manage their condition better.
What could go wrong
This is a very small study (13 participants) with no control group, so results may not apply to everyone. It only looks at short-term tolerance and adherence, not long-term health outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PKU are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.R.N. Santobono-Pausilipon - Ospedale Santobono
Naples, Italy
-
Ospedale San Paolo
Milan, Italy
-
Sant'Orsola-Malpighi Polyclinic (adults)
Bologna, Italy
-
Sant'Orsola-Malpighi Polyclinic (paediatrics)
Bologna, Italy